Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. demonstrates a promising outlook, supported by recent clinical data indicating a statistically significant improvement in median progression-free survival (mPFS) for its product candidate vepdegestrant in patients with ESR1 mutations compared to standard treatments. The potential for greater than four months of mPFS enhancement in this specific population positions vepdeg competitively within the monotherapy market, potentially differentiating it from existing therapies such as imlunestrant and elacestrant. Furthermore, the safety profile of the combination treatments has been validated with no dose-limiting toxicities reported, reinforcing the therapeutic potential and business prospects for Arvinas's innovative drug development.
Bears say
Arvinas Inc. faces significant challenges due to concerns regarding the efficacy of its product candidates, particularly with a lack of demonstrated benefit in the Intent-to-Treat (ITT) population, which could lead to a restricted label and hinder market potential. Additionally, uncertainties surrounding the timing of clinical evidence and competitive risks from other therapies may limit opportunities for Arvinas's lead candidate, vepdegestrant, particularly as studies have not yet begun for crucial phases. The overall financial outlook reflects these challenges, with a notable reduction in price targets and a downgrade in ratings, indicating a cautious sentiment among analysts regarding the company's ability to meet revenue estimates and commercialize its pipeline effectively.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares